ABSTRACT
Objectives What is the most effective pharmacological intervention for glycaemic control in known type 2 diabetes mellitus (DM) without prior insulin treatment and newly started on systemic glucocorticoid therapy?
Design We conducted a systematic literature review.
Data sources We searched MEDLINE, Embase and Cochrane Library databases and Google for articles from 2002 to July 2018.
Eligibility criteria We combined search terms relating to DM (patients, >16 years of age), systemic glucocorticoids, glycaemic control, randomised controlled trials (RCTs) and observational studies.
Data extraction and synthesis We screened and evaluated articles, extracted data and assessed risk of bias and quality of evidence according to Grading of Recommendations Assessment, Development and Evaluation guidelines.
Results Eight of 2365 articles met full eligibility criteria. Basal-bolus insulin (BBI) strategy for patients under systemic glucocorticoid therapy was comparatively effective but provided insufficient glucose control, depending on time of day. BBI strategy with long-acting insulin and neutral protamine Hagedorn as basal insulin provided similar overall glycaemic control. Addition of various insulin strategies to standard BBI delivered mixed results. Intermediate-acting insulin (IMI) as additional insulin conferred no clear benefits, and glycaemic control with sliding scale insulin was inferior to BBI or IMI. No studies addressed whether anticipatory or compensatory insulin adjustments are better for glycaemic control.
Conclusion The lack of suitably designed RCTs and observational studies, heterogeneity of interventions, target glucose levels and glucose monitoring, poor control of DM subgroups and low to moderate quality of evidence render identification of optimal pharmacological interventions for glycaemic control and insulin management difficult. Even findings on the widely recommended BBI regimen as intensive insulin therapy for patients with DM on glucocorticoids are inconclusive. High-quality evidence from studies with well-defined DM phenotypes, settings and treatment approaches is needed to determine optimal pharmacological intervention for glycaemic control.
PROSPERO registration number CRD42015024739.

INTRODUCTION
The worldwide prevalence of type 2 diabetes mellitus (DM) in adults has doubled since 1980 to 8.5% in 2014. While comparatively stable in recent years, the prevalence of hospitalised patients with DM is 25%-40%. Steroid treatment in patients with DM is common. However, steroids are the main cause of drug-induced hyperglycaemia due to their effect of increasing basal endogenous glucose production and lowering insulin sensitivity. Over half of patients receiving high-dose steroids develop hyperglycaemia. Significantly, steroids exacerbate hyperglycaemia in patients with pre-existing DM and enhance the likelihood of complications, length of stay and mortality in these patients.

The importance of detecting and actively managing hyperglycaemia in patients with DM undergoing glucocorticoid therapy is acknowledged. However, current management strategies are suboptimal, and the limited evidence available does not
adequately inform the physician. This is all the more important as the type and doses of administered glucocorticoids and the potencies (and duration of action) of different systemic glucocorticoids vary widely. Shorter courses of steroids may lead to brief periods of hyperglycaemia that do not require further intervention, though hyperglycaemia and other side effects can occur at a wide range of doses. However, longer courses of steroids at higher doses can lead to symptomatic hyperglycaemia. Optimal treatment strategies for glycaemic control are, therefore, vital.

The aim of this study was to conduct a systematic review of treatment strategies for glycaemic control in persons with type 2 DM on diet or oral hypoglycaemic agents (OHA) and newly initiated glucocorticoid therapy. Specifically, we sought to identify the most effective pharmacological intervention for glycaemic control. We evaluated also whether the simultaneous start of insulin with glucocorticoids (anticipatory treatment adjustment) or delayed start of insulin, when blood glucose level (BGL) exceeds normal upper limits (compensatory treatment adjustment), is more effective.

**METHODS**

**Protocol and registration**

The review methods and eligibility criteria were specified in advance, documented in a study protocol, registered online with the International Prospective Register of Systematic Reviews, 31 May 2016, and recorded with a Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We updated the protocol once on 21 October 2016 to broaden inclusion criteria.

**Eligibility criteria**

For eligibility, we followed the Patients, Interventions, Comparisons, Outcomes and Settings (PICOS) criteria. Patients: We included articles on non-critically ill (non-intensive care unit) in-patients or out-patients (>16 years of age) who suffered from type 2 DM treated with diet or OHA (ie, biguanide, glifozins, gliptins, sulfonylureas, glinides, incretins or glitazones) and were started on a once or multiple daily oral or intravenous glucocorticoid therapy (ie, hydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone or fludrocortisone) irrespective of the indication. Interventions: The articles and studies had to address specific treatment interventions for glycaemic control, including, for example, stopping routine DM medication and starting insulin treatment. Comparisons: We included all types of comparisons of the study population with those (1) without DM, (2) without glucocorticoid treatment, (3) with adjusted OHA, or (4) with differing insulin treatments. Outcomes: We accepted outcomes reflecting glycaemic control, that is, time outside target glucose range, mean BGL, hypoglycaemic or hyperglycaemic episodes, and daily insulin dose. Settings: We included randomised controlled trials (RCTs) and observational studies, that is, cohort studies, case–control studies or cross-sectional studies, without imposing any restriction on language, country of origin or publication type. We excluded letters to the editor and conference abstracts. We consulted also guidelines, reviews and expert opinions. We considered only papers published after 2002 because of the subsequent introduction of long-acting insulin; long-acting insulins are, nowadays, an integral part of treatment in insulin-dependent DM.

**Search strategy**

We identified articles based on search terms related to DM and glucocorticoids in the following databases: MEDLINE and PreMEDLINE using OVID, Embase and Cochrane Library electronic databases (online supplementary table 1). The combined use of the databases (PubMed, MEDLINE, Embase and Cochrane) allows coverage of up to 97% of available publications. To enhance coverage further, we conducted also a Google search to retrieve grey literature with exclusive focus on pdf files. The search was conducted on 8 July 2016 and updated on 2 July 2018.

**Study selection**

MT and SKR independently screened a sample of 100 papers by studying the titles and abstracts according to the selection criteria ‘adult persons with pre-existing DM who received a glucocorticoid therapy’. If no abstract was available but the title appeared relevant, MT and SKR reviewed the full text. One abstract was translated from Japanese.

MT and SKR then evaluated the first 100 papers in consensus to establish the basis for consistent screening of all further papers. MT performed the screening of all papers and SKR independently double screened a random sample of 10% of all articles. All articles were assigned to one of the three eligibility groups: ‘yes’, ‘no’ and ‘maybe’. The ‘maybe’ group was discussed by MT and SKR for eligibility after full-text review in a consensus conference. Initial review of eligible articles revealed the necessity for modification of the inclusion criterion ‘≥20 mg/day prednisolone equivalent for ≥5 days’ to ‘intermediate-dose or high-dose glucocorticoid therapy’ because a large number of articles did not specify exact dosages of glucocorticoids.

MT and SKR independently performed a full-text review of all eligible papers for inclusion, considering the PICOS criteria. Disagreements between reviewers were resolved by consensus. Finally, the reference lists of all included articles were screened for additional eligible papers, guidelines and review articles.

**Data extraction and quality assessment**

We extracted the following data from the included articles: study population, participants, and age. Then, we assessed indication, dosage and duration of glucocorticoid therapy, target glucose, insulin strategy, the management of OHA interruption, continuation or adjustment
of dosages and outcome measures, such as time in target glucose range, mean BGL, hypoglycaemic and hyperglycaemic episodes and insulin requirement. Differing assessments were discussed and resolved between MT and SKR.

We used the Cochrane risk of bias tool to evaluate the risk of bias in RCTs and applied the key criteria of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines for observational studies to assess the methodological quality of nonrandomised studies. The overall quality of evidence was assessed using the GRADE criteria.

Data synthesis
We performed a descriptive analysis of RCTs and observational studies. This was because the lack of concordance in the study designs in the included articles precluded the performance of meta-analyses. Included articles were evaluated and compared in detail and the findings were summarised.

Patient or public involvement
Neither the patients nor the public were directly involved in the development of the research question, selection of the outcome measures, design and implementation of the study, or interpretation of the results.

RESULTS
Study inclusion
Our initial search generated 3521 articles. A total of 2365 articles remained after eliminating duplicate entries. Of these, 37 qualified for full-text review. Eight articles met full eligibility criteria, namely, four RCTs with open-label and parallel group designs, one RCT with open-label and cross-over design and three observational studies with a retrospective cohort design (figure 1 and table 1).

The eight articles reported studies that included a total of 481 persons, 343/481 persons with DM and 138/481 persons with glucocorticoid-induced hyperglycaemia. One study included persons with both type 1 and type 2 DM but did not take this distinction into consideration for outcomes. At least 85/481 persons had prior treatment with insulin; three studies did not provide this information. Seven studies included inpatients only, and one study included both inpatients and outpatients. Capillary blood glucose was measured four times a day by continuous glucose monitoring or by using all available capillary and serum blood glucose readings (table 2). The upper limit was a BGL of 10 mmol/L in all studies. The lower BGL limit was 3.9–4.5 mmol/L in all but two studies in which it was 5.6 mmol/L (table 2).

In six studies, authors treated control groups with a basal-bolus insulin (BBI) regimen using insulin glargine as basal insulin, in one study with a BBI regimen using twice-daily insulin detemir, and one study using sliding-scale insulin (SSI) in addition to established DM medication. Strikingly, treatment interventions in the experimental groups diverged substantially. One study compared glycaemic control of BBI regimen in patients with type 2 DM without prednisolone with those with prednisolone treatment. Another study compared glycaemic control of BBI regimen with SSI regimen. One study compared addition of SSI to routine DM medication with the addition of intermediate-acting insulin (IMI). Three studies compared BBI regimens with long-acting insulins to BBI regimens with intermediate-acting neutral protamin Hagedorn (NPH) insulin, but in one of these studies, NPH was given in three equal prandial doses. One study compared BBI regimen with long-acting insulin to the same regimen with the addition of NPH insulin. Finally, the most recent study added the insulin type that matched the glycaemic profile of the administered glucocorticoid. This divergence in study designs of RCTs precluded a clean and coherent quantitative meta-analysis.

BBI strategy in persons under systemic glucocorticoid therapy
Two observational studies report BBI as superior in glucocorticoid-treated patients with type 2 DM. Gosmanov et al found more hyperglycaemic events in patients with type 2 DM under dexamethasone for 3 days (for a hematological malignancy) when treated with SSI therapy compared with a BBI therapy (table 2). In the SSI group, the mean daily BGL was significantly higher (p<0.001), and the average insulin requirement was significantly lower (p<0.001). No hypoglycaemic events occurred in either group, but 3/28 (11%) persons treated with SSI were referred to an intensive care unit because of hyperglycaemic events.

Burt et al studied the effectiveness of a BBI regimen in hospitalised patients with type 2 DM treated with prednisolone in the morning for an acute medical condition compared with those without glucocorticoid treatment. Half of the calculated daily dose was given as long-acting insulin glargine at 21:00 and half as bolus evenly split into three meal dosages of rapid-acting insulin with additional correctional insulin when necessary. The mean daily BGL was significantly higher in the prednisolone group (p<0.001) (table 2). More specifically, BGL was significantly higher at 17:00 and 21:00, but not significantly higher at 07:00 and 12:00. In addition, the daily insulin dose was significantly higher in the prednisolone-treated group than in the control group, especially at 12:00 and 17:00. Thus, BBI treatment provided insufficient glucose control, most notably in the afternoon and evening.

Comparison of BBI regimen with long-acting insulin to NPH as basal insulin
Two RCTs and one observational study compared NPH insulin with the long-acting insulin glargine in a BBI regimen for their efficacy in controlling BGL in...
hospitalised persons treated with medium-dose to high-dose glucocorticoids. The studies differed substantially in their design (table 1). Radhakutty et al included persons with or without type 2 DM who were treated with a single dose of glucocorticoids for respiratory disease or gout. Glargine was administered in the control group and NPH in the experimental group at 07:00. Ruiz de Adana et al studied patients with type 2 DM receiving multiple daily doses of glucocorticoids for respiratory disease. The glargine group received its basal insulin as one dose at 09:00, and the NPH group received it before breakfast, lunch and dinner in three equal doses. Dhital et al retrospectively studied adults treated with prednisone who were on a BBI regimen with either insulin glargine or NPH. Notably, the target glucose range, the time of application and the number of doses of basal insulins were not indicated here, and persons with hyperglycaemia without underlying type 2 DM were also included.

All three studies show a similar overall glycaemic control for NPH or glargine as basal insulin. More specifically, the mean daily BGL and the number of mild hypoglycaemic episodes per day were similar (table 2). Notably, severe hypoglycaemia (BGL <2.22 mmol/L) occurred in two persons in the NPH group in the study by Ruiz de Adana et al. Only Dhital et al found a significantly lower daily insulin requirement in the NPH group.

Figure 1 Flow diagram of study selection. PICOS, patients, interventions, comparisons, outcomes and settings.
## Table 1: Overview of included studies’ characteristics (alphabetical order)

<table>
<thead>
<tr>
<th>First author (year)</th>
<th>Study population</th>
<th>Prednisolone equiv. dose (range or SD) mg; duration</th>
<th>Participants, n (control/exp.); Age average (range or SD)</th>
<th>Intervention in control group</th>
<th>Intervention in experimental group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gerards (2016)</td>
<td>Inpatients or outpatients with or without type 2 DM and hyperglycaemia under cyclic glucocorticoid-containing chemotherapy.</td>
<td>50.4 (36.6–55.3) 3–4 days per cycle.</td>
<td>26 (13/13) • 24 Type 2 DM (13 prior insulin). • 22/26 inpatients 67 years (58–71).</td>
<td>Additional SSI regimen to routine DM medication during prednisone-containing cycles: • Four times daily short-acting insulin according to BGL.</td>
<td>Additional IMI regimen during cycles to routine DM medication: • IMI single morning dose 0.01 IU/mg prednisolone equivalent per kg, max. 0.5 IU/kg; reduced to 40% in &gt;70 years or GFR&lt;60 mL/min; daily increases 10% according to BGL.</td>
</tr>
<tr>
<td>Grommesh (2016)</td>
<td>Inpatients with or without type 2 DM and hyperglycaemia within 24 hours of glucocorticoids for any indication.</td>
<td>57.2 (±31.5) ≤5 days.</td>
<td>61 (31/30) • 30 Type 2 DM (prior insulin n/a) 64.8 years (±16.1).</td>
<td>BBI regimen 1:1 basal and bolus: • Basal: insulin glargine. • Bolus: prandial insulin lispro. • Additional correctional insulin aspart. • Algorithm for initial dosing based on DM diagnosis, HbA1c and previous treatment (see ref).</td>
<td>Additional NPH insulin to BBI regimen: • NPH along with glucocorticoid (three times if multiple dosing). • Algorithm for NPH doses based on glucocorticoid dose and DM diagnosis.</td>
</tr>
<tr>
<td>Lakhani (2018)</td>
<td>Inpatients with or without DM (type 1 or 2) under glucocorticoids for any indication with postprandial hyperglycaemia.</td>
<td>20.75 (±12.7) Duration n/a.</td>
<td>67 (34/33) • DM (type and prior insulin n/a) in 14 control/21 experimental 54.2 years (±11.9).</td>
<td>BBI regimen 1:1 basal and bolus, 0.3–0.5 IU/kg/day according to HbA1c: • Basal: insulin glargine at bedtime. • Bolus: prandial insulin lispro. • Additional correctional insulin lispro.</td>
<td>Additional correctional insulin which matches glycaemic profile of the glucocorticoid administered according protocol (see ref) given along with glucocorticoid: • regular insulin with hydrocortisone. • NPH with prednisolone or methylprednisolone. • Insulin glargine with dexamethasone.</td>
</tr>
<tr>
<td>Radhakutty (2017)</td>
<td>Inpatients with or without type 2 DM and hyperglycaemia under glucocorticoids for COPD, pneumonia, interstitial lung disease or gout.</td>
<td>33 (±9.6) &gt;1 day.</td>
<td>48 (23/25) • 34 Type 2 DM (10 prior insulin) 72.1 years (±11.5).</td>
<td>BBI regimen 1:1 basal and bolus, 0.5IU/kg/day: • Basal: insulin glargine. • Bolus: prandial insulin aspart in three equal doses. • Additional correctional insulin if needed.</td>
<td>BBI regimen 1:1 basal and bolus • Basal: NPH insulin, morning dose. • Bolus: prandial insulin aspart, 20% before breakfast, 40% before lunch and 40% before dinner. • additional correctional insulin if needed.</td>
</tr>
</tbody>
</table>

Continued
Table 1  Continued

<table>
<thead>
<tr>
<th>First author (year)</th>
<th>Study population</th>
<th>Prednisolone equiv. dose (range or SD) mg; duration</th>
<th>Participants, n (control/exp.); Age average (range or SD)</th>
<th>Intervention in control group</th>
<th>Intervention in experimental group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ruiz de Adana (2016)</td>
<td>Inpatients with type 2 DM on pneumology under glucocorticoid treatment for respiratory disease.</td>
<td>Approx. 100 mg, day 1; approx. 33 mg, day 6.</td>
<td>53 (27/26) 68.6 years (±7.3) years.</td>
<td>BBI regimen 1:1 basal and bolus, 0.3–0.5 IU/kg/day or regular insulin dose multiplied by 1.5:  • Basal: insulin glargine at 08:00.  • Bolus: prandial insulin glulisine in three equal doses.  • Additional correctional insulin if needed.</td>
<td>BBI regimen 1:1 basal and bolus, 0.3–0.5 IU/kg/d or regular insulin dose multiplied by 1.5:  • Basal: NPH insulin in three equal prandial doses.  • Bolus: prandial insulin glulisine in three equal doses.  • additional correctional insulin if needed.</td>
</tr>
<tr>
<td>Ruipérez et al. (2015)</td>
<td>Inpatients with type 2 DM with or without glucocorticoid treatment for respiratory disease.</td>
<td>33.2±9.0, day 1 21.1±7.2, day 5.</td>
<td>66 (42/24) 75.7 years (±12.9).</td>
<td>BBI regimen 1:1 basal and bolus, 0.3–0.4 IU/kg/day:  • Basal: insulin glargine.  • Bolus: insulin aspart or lispro or glulisin, divided into three meal time bolus.  • Additional correctional insulin if needed.</td>
<td>BBI regimen as control and additional prednisolone single morning dose&gt;3 days.</td>
</tr>
<tr>
<td>Dhital (2012)</td>
<td>Inpatients with or without type 2 DM treated with prednisolone at day before discharge; comparison of NPH insulin versus insulin glargine in BBI regimen.</td>
<td>31±24.4</td>
<td>120 (60/60) 58 years (±14).</td>
<td>BBI regimen 1:1 basal and bolus:  • Basal: insulin glargine.  • Bolus: insulin aspart.  • Additional correctional insulin if needed.</td>
<td>BBI regimen 1:1 basal and bolus insulin:  • Basal: NPH insulin.  • Bolus: regular insulin.  • Additional correctional insulin if needed.</td>
</tr>
<tr>
<td>Gosmanov (2013)</td>
<td>Inpatients with type 2 DM treated with dexamethasone for hematological malignancies.</td>
<td>57.2±9.9</td>
<td>40 (12/28) 56.1 years (±7.8).</td>
<td>BBI regimen 1:1 basal and bolus, 0.33 IU/kg/day:  • Basal: insulin detemir twice daily.  • Bolus: insulin aspart.  • Additional correctional insulin if needed.  • Daily insulin dose correction if out of target 20%–30%.</td>
<td>SSI regimen with regular insulin (for protocol, see ref.)</td>
</tr>
</tbody>
</table>

BBI, basal-bolus insulin; BGL, blood glucose level; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; IMI, intermediate-acting insulin; n/a, not applicable; NPH, neutral protamine Hagedorn, isophane insulin; SSI, sliding-scale insulin
## Table 2  Outcomes of included original articles (alphabetic order)

<table>
<thead>
<tr>
<th>First author</th>
<th>Target glucose (mmol/L)</th>
<th>Glycaemic control</th>
<th>Mean daily BGL (mmol/l)</th>
<th>Hypoglycaemia &lt;3.9 mmol/L</th>
<th>Hyperglycaemia &gt;16.7 mmol/L</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Control</td>
<td>Exper.</td>
<td>p value</td>
<td>Control</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Time in target glucose range (%)</td>
<td>Mean total daily insulin dose (IU/kg/day or IU/day)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomised control trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gerards[27]</td>
<td>3.9–10</td>
<td>20.9*</td>
<td>34.3*</td>
<td>&lt;0.001</td>
<td>13.5±2.8*</td>
<td>12.4±2.9*</td>
</tr>
<tr>
<td>Grommesh[23]</td>
<td>3.9–10</td>
<td>54.6†</td>
<td>62.0†</td>
<td>0.24</td>
<td>9.9±1.7†</td>
<td>9.4±2.0†</td>
</tr>
<tr>
<td>Lakhani[33]</td>
<td>5.6–10</td>
<td>15.0‡</td>
<td>33.1‡</td>
<td>0.002</td>
<td>12.3±2.8‡</td>
<td>9.5±1.9‡</td>
</tr>
<tr>
<td>Radhakutty[35]</td>
<td>4–10</td>
<td>50.²</td>
<td>58.² 5</td>
<td>0.28</td>
<td>11.8 ±2.5</td>
<td>10.5 ²5</td>
</tr>
<tr>
<td>Ruiz de Adana[36]</td>
<td>4.5–10</td>
<td>42*</td>
<td>38*</td>
<td>0.61</td>
<td>10.8±2.9*</td>
<td>11.1±3.5§</td>
</tr>
<tr>
<td>Observational studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burt[38]</td>
<td>4–10</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>10±0.1†</td>
<td>12.2±0.3†</td>
</tr>
<tr>
<td>Dhital[39]</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>9.2±2.9**</td>
<td>9.3±2.6**</td>
</tr>
<tr>
<td>Gosmanov[40]</td>
<td>5.6–10</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>12.2±2.8**</td>
<td>16.7±3.2**</td>
</tr>
</tbody>
</table>

*Indicates continuous glucose monitoring.
†Capillary blood glucose monitoring four times a day (three times before meals and at bedtime).
‡Premeal blood glucose in target range; premeal target range defined as BGL 5.6–7.8 mmol/L.
§Bedtime blood glucose in target range; bedtime target range defined as BGL 7.8–9.9 mmol/L.
¶Capillary blood glucose monitoring premeal and 2 hours post meal.
**All available BGL.
††Approximation, because article indicates ‘time outside target glucose range’. BGL, blood glucose level; IMI, intermediate-acting insulin; MAGE, mean amplitude of glycaemic excursions; n/a: not applicable; SSI, sliding scale insulin.
Addition of insulin to established DM medication

Gerards et al. compared the addition of SSI insulin compared with IMI to established DM medication for glycaemic control. The types of insulin were not further defined. Half of the persons had prior insulin treatment. The addition of IMI resulted in significantly longer time in target glucose range (p<0.001) and lower mean daily BGL (p<0.05). This was achieved with an increased insulin requirement in the IMI group. Remarkably, the mean daily BGL of both groups (SSI 13.5±2.8, IMI 12.4±2.9) was higher than those of all other studies (table 2).

Two RCTs added insulin to an existing BBI regimen in persons with or without type 2 DM (33, 34) (table 1). Grommesh et al. studied the addition of NPH insulin together with a glucocorticoid to a BBI regimen. The algorithm for NPH dosing was based on glucocorticoid type, dose and pre-existing DM diagnosis. The study showed that there was no advantage in this for glycaemic control, mean total daily insulin dose, or hypoglycaemia and hyperglycaemia (table 2). Similarly, an RCT by Lakhani et al. studied the addition of a so-called ‘correctional insulin’ together with the glucocorticoid to a BBI regimen. The type of correctional insulin matched the glycaemic profile of the type of administered glucocorticoid, for example, NPH insulin for prednisolone or insulin glargine for dexamethasone treatment.33 Correctional insulin significantly improved ‘time in target premeal glucose range’ (defined as 5.6–10 mmol/L. (p=0.002) and mean daily BGL (p=0.0001) but not time in ‘bedtime target glucose range’ (p=0.09). The hyperglycaemic events were reduced (p<0.001). No data were provided on subgroups without DM or with type 1 DM and on daily insulin doses.

Anticipatory or compensatory approach to glycaemic control

We aimed to determine whether anticipatory or compensatory adjustments are better for glycaemic control. No screened or included study addressed this issue. While screening articles, we found some recommendations about this in guidelines and reviews and we address this issue in the discussion section.

Risk of bias and grading of evidence

Risk of bias was assessed in five RCTs for seven domains and four outcomes (mean BGL, time in target glucose, daily insulin dose and hypoglycaemia) (online supplementary table 2a). All RCTs were unblinded for participants and personnel. Although placebo effects are very unlikely, unblinding may have affected the attention of staff. This might be the most relevant risk for bias in these studies. The lack of random sequence generation and allocation concealment might be another common bias. The three observational studies were classified as having low,38 middle39 and high40 ranges of risk of bias (online supplementary table 2b). The most common risk of bias was the failure to control confounding. Notably, an overall risk of bias of an outcome for all five RCTs is not so informative because the treatment interventions were not comparable.

Applying the GRADE criteria on each individual study, we had to decrease the level of evidence for the primary outcomes ‘mean BGL’ and ‘time in target glucose range.’ This was mainly because of risk of bias and publication bias and because of inconsistency and imprecision in the five RCTs and one observational study (for the overall rating of quality of evidence in RCTs and observational studies, see online supplementary table 3). Hence, we classified the overall quality of evidence for the individual interventions as moderate,33 36–37 low35 38–39 or very low.34 40

DISCUSSION

Glucocorticoid treatment inevitably leads to hyperglycaemia in persons with type 2 DM. We systematically reviewed the available evidence on pharmacological interventions for effective glycaemic control. We found, first, that there is some uncertainty as to the optimal management of glucocorticoid-induced hyperglycaemia in DM. The lack of studies reporting high-quality evidence makes it difficult to provide formal and final recommendations. This review shows that the available evidence is of low to moderate quality. Second, the reviewed studies speak in favour of the use of BBI without a specific preference for long-acting or IMI as basal insulin, but these studies do indicate that SSI should be abandoned. Third, two studies suggested that pharmacodynamic profiles of insulins should be reconciled with corresponding profiles of glucocorticoids. However, there is insufficient evidence to recommend this. Finally, the reviewed studies do not clarify whether one should initiate anticipatory or compensatory insulin treatment.

BBI is widely accepted and recommended as intensive insulin therapy in DM. However, the question remains whether BBI performs best in type 2 DM under glucocorticoid treatment. Five open-label RCTs and three observational studies included in this systematic review address this issue. Gosmanov et al. shows that BBI is better than SSI in terms of glycaemic control. This is in line with data from various clinical settings that support improved hyperglycaemic control using BBI compared with SSI. Gerards et al. corroborates that SSI delivers poorer control compared with IMI when used as an addition to the routine DM regimen. Although very popular among non-endocrinologists, these findings suggest that SSI treatment should not be prescribed in this setting anymore. On the other hand, Burt et al. did find that glycaemic control was insufficient at 17:00 and 21:00 when using BBI with long-acting insulin in patients with type 2 DM treated with prednisolone compared with those without prednisolone treatment. These findings are in line with previous reports of afternoon and evening hyperglycaemia under glucocorticoids in persons without DM. Thus, BBI with long-acting insulin does not offer a final solution.

The intermediate-acting NPH insulin provides good control of afternoon peaks of blood glucose caused by glucocorticoids. This approach might have an advantage
over long-acting insulin because its effects show a similar timeline to that of glucocorticoid-induced afternoon peaks of hyperglycaemia.\(^\text{35-57}\) Three of the reviewed articles\(^\text{35,36,39}\) compared NPH insulin with insulin glargine as basal insulin in a BBI treatment in randomised controlled\(^\text{35-36}\) and retrospective\(^\text{39}\) studies, finding no significant differences in glycaemic control. However, NPH insulin caused more hypoglycaemic events when NPH and bolus insulin were administered in equal preprandial doses for the purpose of controlling hyperglycaemia in persons receiving multiple daily doses of glucocorticoids.\(^\text{36}\) Such a protocol may not be flexible enough in that it does not give sufficient consideration to the night-time fasting period and the associated risk of nocturnal hypoglycaemia. Insulin requirement, however, was higher in BBI with long-acting insulin compared with NPH as basal insulin in two of the studies\(^\text{36,39}\) but it was similar in the other.\(^\text{35}\) The addition of NPH together with the glucocorticoid in the BBI treatment also failed to improve glycaemic control.\(^\text{34}\) The most recent study by Lakhani et al.\(^\text{33}\) suggests a unique approach to better match the pharmacodynamic properties of insulins and glucocorticoids. This resulted in significantly lower mean daily BGL and premeal time in target glucose range. While the approach of Lakhani et al.\(^\text{33}\) appears to be promising, it does need to be corroborated in a larger study.

We found no primary data comparing anticipatory with compensatory treatment adjustments for glycaemic control when starting glucocorticoids. This lack of data is a source of some divergence in expert opinions in guidelines. The American Endocrine Society Clinical Practice Guidelines\(^\text{41}\) recommends an anticipatory approach with discontinuation of OHA at the time of hospital admission and initiation of insulin with persistent hyperglycaemia. In exceptional cases, selected persons who are stable, eating regularly and have no contraindication ‘may be candidates for continuation of previously prescribed OHA’. The Canadian Diabetes Association guideline\(^\text{45}\) recommends that ‘glycaemic monitoring for 48 hours after initiation of steroids may be considered’. In contrast, the Joint British Diabetes Societies for inpatient care guideline,\(^\text{19}\) and the Imperial College Clinical Guidance\(^\text{58}\) recommend the up-titration of OHA first. They recommend adding\(^\text{19}\) or switching\(^\text{58}\) to insulin if BGL remains above 10 mmol/L. Reports of experience or evidence to suggest the use of DDP-4 inhibitors, GLP-1 receptor agonists or SGLT-2 inhibitors are lacking.

The strength of our systematic review is that it makes an important contribution to DM management. It does this by highlighting the unresolved challenge of good glycaemic control in patients with DM who are on systemic glucocorticoid therapy and by reporting an extensive literature search on hyperglycaemic control in these patients. However, we cannot draw conclusions from our systematic analysis on the most effective management approach. This is largely due to the low to moderate quality of available evidence and the lack of comparability between the reviewed studies. In fact, this review draws attention to the heterogeneity of the experimental designs and the lack of well-powered, high-quality studies. Given that the populations, interventions, target glucose levels and glucose monitoring differed from study to study, the main limitation is that we can only provide a descriptive review of the studies but not formal recommendations. Well-designed studies with more homogeneous patient populations are needed in order to answer the questions raised in this review. The present review focused on the population of persons with pre-existing type 2DM without prior insulin treatment. However, we included articles with mixed populations, namely, persons with type 2DM with or without prior insulin treatment and type 1DM, because there is an insufficient number of articles with the specific subgroup of interest. We acknowledge that this is not standard practice in systematic reviews.

**CONCLUSION**

Glucocorticoid therapy exacerbates hyperglycaemia in patients with pre-existing DM. Current management strategies give insufficient guidance for glycaemic control in persons started on glucocorticoids. The lack of relevant RCTs and observational studies, heterogeneity of populations, interventions, target glucose levels and glucose monitoring in available studies, and low to moderate quality of available evidence make it difficult to identify pharmacological interventions for effective glycaemic control. Even for the widely recommended use of a BBI regimen as intensive insulin therapy in DM, the data on this regimen in patients with DM on glucocorticoids is inconclusive. Indeed, the findings of our systematic review clearly speak in favour of the call to action on research in inpatient DM management of The PRIDE group\(^\text{59}\) and in outpatient care. A concerted effort of diabetes societies would be needed to develop powerful study designs that take into account different DM phenotypes, settings and treatment approaches.

**Contributors** MT drafted the study; contributed to the development of the selection criteria and data extraction criteria; developed the search strategy; elaborated the study selection, data extraction and data synthesis; wrote the manuscript; provided feedback and approved the final manuscript. RL provided expertise on diabetes mellitus, read the manuscript, provided feedback and approved the final manuscript. MC contributed to the writing of the manuscript. AN read, provided feedback and approved the final manuscript. EB drafted the study; contributed to the development of the selection criteria and data extraction criteria; read the manuscript, provided feedback and approved the final manuscript. SKR is the guarantor; drafted the study; contributed to the development of the selection criteria and data extraction criteria; did the study selection, data extraction and data synthesis; wrote the manuscript; provided feedback and approved the final manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** All data relevant to the study are included in the article or uploaded as supplementary information.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES


